Privia Health surges 5% on Q4 beat, strong FY26 guidance
Healthcare technology firm raises EBITDA outlook 20%, boosted by $480M cash position
Privia Health Group shares jumped 5.2% on Thursday after the population health technology company reported stronger-than-expected fourth-quarter results and raised its 2026 guidance, highlighting the momentum behind its physician practice platform.
The Arlington, Virginia-based company delivered adjusted earnings per share of $0.25 for the quarter, beating analyst estimates by 15.3%, while revenue climbed to $541.2 million, exceeding the $495.9 million consensus forecast and representing a 9.1% year-over-year increase, according to the company's earnings release.
The performance capped a robust 2025 fiscal year, with full-year revenue reaching $2.12 billion, up 22.3% from the previous year. Adjusted EBITDA surged 38.8% to $125.5 million, landing at the high end of the company's guidance range and underscoring the profitability improvements driving the business model.
"All 2025 operating and financial metrics came in at or above the high end of our guidance ranges," the company stated in its earnings announcement, pointing to successful execution across its physician network and value-based care initiatives.
Looking ahead, Privia outlined an ambitious path for 2026, projecting adjusted EBITDA of $145 million to $155 million, representing growth of 15.5% to 23.5% compared to 2025. The guidance includes approximately 80% conversion of EBITDA to free cash flow, a metric that highlights the company's capital efficiency.
The company expects to expand its physician network to between 5,900 and 6,000 implemented providers, an increase of 9.7% to 11.5% from 2025 levels. Practice collections are projected to reach $3.65 billion to $3.75 billion, while attributed lives should grow to between 1.55 million and 1.6 million patients under management.
A key pillar of Privia's financial strength is its fortress-like balance sheet. As of December 31, the company held $479.7 million in cash with no debt, providing substantial flexibility for strategic investments and potential acquisitions in the consolidating healthcare services market. The company's total stockholders' equity stands at $790.9 million against a modest $578.4 million in total liabilities.
Wall Street analysts have maintained a largely positive outlook on Privia Health, with 19 of 21 analysts covering the stock rating it as either "buy" or "strong buy" and just two recommending "hold," according to MarketBeat data. The consensus price target of $31.25 represents significant upside from the current level.
Privia's business model focuses on helping independent physician practices navigate the transition to value-based care by providing technology, practice management services, and population health tools. The company leverages scale to improve practice economics while capturing data that enables better patient outcomes and cost management—a combination that has proven increasingly attractive amid healthcare's ongoing payment reform.
The strong performance reflects broader trends in the healthcare sector, where physician practice management and value-based care platforms have gained traction as providers seek to maintain independence while participating in risk-sharing arrangements with insurers. Privia's growth has been driven by both organic provider additions and strategic acquisitions that expand its geographic footprint.
Despite Thursday's gains, Privia shares remain below their 52-week high of $26.51 reached earlier this year, suggesting some investors may be taking a wait-and-see approach to the sustainability of the company's growth trajectory. The stock's relatively high forward price-to-earnings multiple of 38 reflects expectations for continued expansion, but also creates vulnerability if execution stumbles.
With $480 million in available cash and no debt maturities on the horizon, Privia has the financial runway to pursue further strategic priorities, whether through network expansion, technology investments, or selective acquisitions that could accelerate its path to scale in the fragmented primary care market.